Pituitary Tumor Unit, Endocrinology Department, Hospital CUF Descobertas, Lisbon, Portugal.
Faculdade de Medicina, Universidade Católica Portuguesa, Lisbon, Portugal.
Clin Endocrinol (Oxf). 2024 Jun;100(6):542-557. doi: 10.1111/cen.15053. Epub 2024 Mar 28.
Pseudoacromegaly encompasses conditions with features of acromegaly/gigantism, but no growth hormone (GH) or insulin-like growth factor-1 (IGF-1) excess. We aimed to review published pseudoacromegaly cases evaluated due to clinical suspicion of acromegaly.
DESIGN/PATIENTS: PubMed/Medline search was conducted to identify reported pseudoacromegaly cases, which were systematically reviewed to ensure they met eligibility criteria: (1) presentation suggestive of acromegaly; (2) acromegaly excluded based on normal GH, IGF-1 and/or GH suppression on oral glucose tolerance test (OGTT-GH); (3) diagnosis of the pseudoacromegaly condition was established. Data were retrieved from each case and analysed collectively.
Of 76 cases, 47 were males, mean ages at presentation and at first acromegaloid symptoms were 28 ± 16 and 17 ± 10 years, respectively. Most common conditions were pachydermoperiostosis (47%) and insulin-mediated pseudoacromegaly (IMP) (24%). Acromegaloid facies (75%) and acral enlargement (80%) were the most common features. Measurement of random GH was reported in 65%, IGF-1 in 79%, OGTT-GH in 51%. GH excess was more frequently excluded based on two tests (53%). Magnetic resonance imaging (MRI) was performed in 30 patients, with pituitary adenoma or hyperplasia being reported in eight and three patients, respectively. Investigations differed between cases managed by endocrine and non-endocrine specialists, the former requesting more often IGF-1, OGTT-GH and pituitary MRI.
Pseudoacromegaly is a challenging entity that may be encountered by endocrinologists. Pachydermoperiostosis and IMP are the conditions most often mimicking acromegaly. Adequate assessment of GH/IGF-1 is crucial to exclude acromegaly, which may be better performed by endocrinologists. Pituitary incidentalomas are common and require careful judgement to prevent unnecessary pituitary surgery.
假性肢端肥大症包括具有肢端肥大症/巨人症特征但生长激素(GH)或胰岛素样生长因子-1(IGF-1)不超标的疾病。我们旨在综述因疑似肢端肥大症而接受评估的已发表的假性肢端肥大症病例。
设计/患者:通过 PubMed/Medline 搜索,确定报道的假性肢端肥大症病例,并对其进行系统回顾,以确保符合纳入标准:(1)有肢端肥大症表现;(2)根据口服葡萄糖耐量试验(OGTT-GH)时 GH、IGF-1 和/或 GH 抑制正常排除肢端肥大症;(3)确诊为假性肢端肥大症。从每个病例中检索数据并进行综合分析。
76 例患者中,男性 47 例,就诊时和首次出现肢端肥大样症状时的平均年龄分别为 28±16 岁和 17±10 岁。最常见的疾病是厚皮骨膜病(47%)和胰岛素介导的假性肢端肥大症(IMP)(24%)。肢端肥大样面容(75%)和肢端增大(80%)是最常见的特征。65%的病例报告了随机 GH 测量值,79%报告了 IGF-1,51%报告了 OGTT-GH。GH 过多更常根据两项检查排除(53%)。30 例患者进行了磁共振成像(MRI)检查,分别有 8 例和 3 例报告发现垂体腺瘤或增生。内分泌和非内分泌专家管理的病例之间的检查存在差异,前者更常要求检查 IGF-1、OGTT-GH 和垂体 MRI。
假性肢端肥大症是一种具有挑战性的疾病,内分泌科医生可能会遇到。厚皮骨膜病和 IMP 是最常模拟肢端肥大症的疾病。充分评估 GH/IGF-1 对于排除肢端肥大症至关重要,而内分泌科医生可能更擅长进行这种评估。垂体偶发瘤很常见,需要仔细判断以防止不必要的垂体手术。